Bioceres Crop Solutions Corp (NASDAQ:BIOX) is set to release its Q2 2025 earnings on Feb 12, 2025. The consensus estimate for Q2 2025 revenue is $129.50 million, and the earnings are expected to ...

Reports Q2 revenue $106.7M vs. $140.2M last year. Mr. Federico Trucco, Bioceres (BIOX)’ Chief Executive Officer, commented: “Calendar year 2024 ...

View Bioceres Crop Solutions Corp. (BIOX) current and estimated P/E ratio data provided by Seeking Alpha.

Lake Street analyst Ben Klieve maintained a Buy rating on Bioceres Crop Solutions (BIOX – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $5.55.

The proceeds will allow the company to deliver full results from BIRCH, its Phase 2a trial of BIOX-101 to treat intracerebral hemorrhage (ICH), an orphan disease with no currently approved ...

By establishing a stronger regional presence in APAC, Bio X Cell aims to better support its customers in one of the world's most dynamic and rapidly growing biomedical research markets.